Drug giant Pfizer isn’t ready to abandon neuroscience — here’s its ‘star cluster’ strategy for betting on promising brain drug startups
|01/15/2019||Posted by BusinessMediaguide.Com under General World News||
- Last year, after several failures related to Alzheimer’s disease drugs, pharmaceutical giant Pfizer announced it was stepping away from neuroscience research and development.
- The company isn’t completely done with the field. It partnered with Bain Capital in October to launch neuroscience spinoff Cerevel Therapeutics.
- Cerevel is part of a much larger strategy to maintain a presence in neuroscience, Pfizer Ventures executives explained in an interview with Business Insider during the J.P. Morgan Healthcare Conference.